Angiostatin binds to tyrosine kinase substrate annexin II through the lysine-binding domain in endothelial cells

Microvascular Research

Volumn 64, Issue 3, 2002, Pages 448-462

  Tuszynski, George P ^a,c   Sharma, Meena R ^b   Rothman, Vicki L ^a,c   Sharma, Mahesh C ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Temple University   (United States)

Author keywords

Angiogenesis; Angiostatin; Annexin II; Extracellular matrix; Fibrinolysis; Kringle 1 4; Plasmin; Plasminogen; Proteolysis

Indexed keywords

AMINOCAPROIC ACID; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ISOENZYME; LIPOCORTIN 2; MONOCLONAL ANTIBODY; PEPTIDE DERIVATIVE; PROTEIN ANTIBODY; PROTEIN TYROSINE KINASE; RECEPTOR; SERYLLEUCYLTYROSYLTYROSYLISOLEUCYLGLUTAMINYLGLUTAMINYLASPARTYLTHREONYLLYSIN E; SERYLTYROSYLSERYLPROLYLTYROSYLASPARTYLMETHIONYLLEUCYLGLUTAMYLSERYLISOLEUCYL LYSINE; UNCLASSIFIED DRUG; FIBRIN; LIGAND; LYSINE; PEPTIDE; PEPTIDE FRAGMENT; PLASMINOGEN;

ANIMAL CELL; AORTA; ARTERY ENDOTHELIUM; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; DRUG BINDING SITE; DRUG INHIBITION; DRUG MECHANISM; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; ENZYME SUBSTRATE; FIBROBLAST; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN IMMOBILIZATION; PROTEIN PURIFICATION; SEQUENCE HOMOLOGY; SOLID; ANGIOGENESIS; ANIMAL; CATTLE; CELL CULTURE; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; EXTRACELLULAR MATRIX; IMMUNOBLOTTING; KINETICS; METABOLISM; MICROCIRCULATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; SERODIAGNOSIS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

BOVINAE; MUS MUSCULUS;

ANGIOSTATINS; ANIMALS; ANNEXIN A2; CATTLE; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; FIBRIN; HUMANS; IMMUNOBLOTTING; KINETICS; LIGANDS; LYSINE; MICROCIRCULATION; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDE FRAGMENTS; PEPTIDES; PLASMINOGEN; PRECIPITIN TESTS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 0036435179     PISSN: 00262862     EISSN: None     Source Type: Journal    
DOI: 10.1006/mvre.2002.2444     Document Type: Article

References (58)

1. Aitkenhead, M., Wang, S. J., Nakatsu, M. N., Mestas, J., Heard, C., and Hughes, C. C. (2002). Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: Induction of ESM-1, betaig-h3, and NrCAM. Microvasc. Res. 63, 159-171.
2. Astrup, T. (1991). Fibrinolysis: Past and present, a reflection of fifty years. Semin. Thromb. Hemost. 17, 161-174.
3. Bajou, K., Masson, V., Gerard, R. D., Schmitt, P. M., Albert, V., Praus, M., Lund, L. R., Frandsen, T. L., Brunner, N., Dano, K., Fusenig, N. E., Weidle, U., Carmeliet, G., Loskutoff, D., Collen, D., Carmeliet, P., Foidart, J. M., and Noel, A. (2001). The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: Implications for antiangiogenic strategies. J. Cell Biol. 152, 777-784.
4. Bergers, G., Javaherian, K., Lo, K. M., Folkman, J., and Hanahan, D. (1999). Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808-812.
5. Blei, F., Wilson, E. L., Mignatti, P., and Rifkin, D. B. (1993). Mechanism of action of angiostatic steroids: Suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J. Cell. Physiol. 155, 568-578.
6. Boyko, V., Mudrak, O., Svetlova, M., Negishi, Y., Ariga, H., and Tomilin, N. (1994). A major cellular substrate for protein kinases, annexin II, is a DNA-binding protein. FEBS Lett. 345, 139-142.
7. Brambilla, R., Zippel, R., Sturani, E., Morello, L., Peres, A., and Alberghina, L. (1991). Characterization of the tyrosine phosphorylation of calpactin I (annexin II) induced by platelet-derived growth factor. Biochem. J. 278, 447-452.
8. Brodsky, S., Chen, J., Lee, A., Akassoglou, K., Norman, J., and Goligorsky, M. S. (2001). Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis. Am. J. Physiol. Heart Circ. Physiol. 281, H1784-H1792.
9. Carmeliet, P., Mulligan, R. C., and Collen, D. (1994). Transgenic animals as tools for the study of fibrinolysis in vivo. J. Intern. Med. 236, 455-459.
10. Chen, C., Parangi, S., Tolentino, M. J., and Folkman, J. (1995). A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Res. 55, 4230-4233.
11. Chiang, Y., Davis, R. G., and Vishwanatha, J. K. (1996). Altered expression of annexin II in human B-cell lymphoma cell lines. Biochim. Biophys. Acta 1313, 295-301.
12. Chiang, Y., Rizzino, A., Sibenaller, Z. A., Wold, M. S., and Vishwanatha, J. K. (1999). Specific down-regulation of annexin II expression in human cells interferes with cell proliferation. Mol. Cell. Biochem. 199, 139-147.
13. Chung, C. Y., Murphy-Ullrich, J. E., and Erickson, H. P. (1996). Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol. Biol. Cell 7, 883-892.
14. Claesson-Welsh, L., Welsh, M., Ito, N., Anand-Apte, B., Soker, S., Zetter, B., O'Reilly, M., and Folkman, J. (1998). Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc. Natl. Acad. Sci. USA 95, 5579-5583.
15. Dubois, T., Oudinet, J. P., Russo-Marie, F., and Rothhut, B. (1995). In vivo and in vitro phosphorylation of annexin II in T cells: Potential regulation by annexin V. Biochem. J. 310, 243-248.
16. Felez, J., Miles, L. A., Fabregas, P., Jardi, M., Plow, E. F., and Lijnen, R. H. (1996). Characterization of cellular binding sites and interactive regions within reactants required for enhancement of plasminogen activation by tPA on the surface of leukocytic cells. Thromb. Haemost. 76, 577-584.
17. Folkman, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31.
18. Folkman, J., and Shing, Y. (1992). Angiogenesis. J. Biol. Chem. 267, 10931-10934.
19. Hajjar, K. A., Jacovina, A. T., and Chacko, J. (1994). An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J. Biol. Chem. 269, 21191-21197.
20. Hajjar, K. A., and Krishnan, S. (1999). Annexin II: A mediator of the plasmin/plasminogen activator system. Trends Cardiovasc. Med. 9, 128-138.
21. Hajjar, K. A., and Menell, J. S. (1997). Annexin II: A novel mediator of cell surface plasmin generation. Ann. NY Acad. Sci. 811, 337-449.
22. Hall, S. W., Humphries, J. E., and Gonias, S. L. (1991). Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin. J. Biol. Chem. 266, 12329-12336.
23. Hanahan, D., and Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364.
24. Hayes, M. L., and Castellino, F. J. (1979). Carbohydrate of the human plasminogen variants. III. Structure of the O-glycosidically linked oligosaccharide unit. J. Biol. Chem. 254, 8777-8780.
25. Henkin, J., Marcotte, P., and Yang, H. C. (1991). The plasminogen-plasmin system. Prog. Cardiovasc. Dis. 34, 135-164.
26. Holmgren, L., O'Reilly, M. S., and Folkman, J. (1995). Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1, 149-153.
27. Ji, W. R., Castellino, F. J., Chang, Y., Deford, M. E., Gray, H., Villarreal, X., Kondri, M. E., Marti, D. N., Llinas, M., Schaller, J., Kramer, R. A., and Trail, P. A. (1998). Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB J. 12, 1731-1738.
28. (2+) signaling in endothelial cells by the angiogenesis inhibitors endostatin and angiostatin. Am. J. Physiol. Cell Physiol. 280, C1140-C1150.
29. Kang, H. M., Choi, K. S., Kassam, G., Fitzpatrick, S. L., Kwon, M., and Waisman, D. M. (1999). Role of annexin II tetramer in plasminogen activation. Trends Cardiovasc. Med. 9, 92-102.
30. Kassam, G., Choi, K. S., Ghuman, J., Kang, H. M., Fitzpatrick, S. L., Zackson, T., Zackson, S., Toba, M., Shinomiya, A., and Waisman, D. M. (1998). The role of annexin II tetramer in the activation of plasminogen. J. Biol. Chem. 273, 4790-4799.
31. Keutzer, J. C., and Hirschhom, R. R. (1990). The growth-regulated gene 1B6 is identified as the heavy chain of calpactin I. Exp. Cell Res. 188, 153-159.
32. Liotta, L. A., Goldfarb, R. H., Brundage, R., Siegal, G. P., Terranova, V., and Garbisa, S. (1981). Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res. 41, 4629-4636.
33. Lucas, R., Holmgren, L., Garcia, I., Jimenez, B., Mandriota, S. J., Borlat, F., Sim, B. K., Wu, Z., Grau, G. E., Shing, Y., Soff, G. A., Bouck, N., and Pepper, M. S. (1998). Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 92, 4730-4741.
34. Luo, J., Lin, J., Paranya, G., and Bischoff, J. (1998). Angiostatin upregulates E-selectin in proliferating endothelial cells. Biochem. Biophys. Res. Commun. 245, 906-911.
35. Masaki, T., Tokuda, M., Fujimura, T., Ohnishi, M., Tai, Y., Miyamoto, K., Itano, T., Matsui, H., Watanabe, S., Sogawa, K., et al. (1994). Involvement of annexin I and annexin II in hepatocyte proliferation: Can annexins I and II be markers for proliferative hepatocytes? Hepatology 20, 425-435.
36. Moser, T. L., Stack, M. S., Asplin, I., Enghild, J. J., Hojrup, P., Everitt, L., Hubchak, S., Schnaper, H. W., and Pizzo, S. V. (1999). Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Sci. USA 96, 2811-2816.
37. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. (1997). Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285.
38. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. (1996). Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2, 689-692.
39. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Cao, Y., Moses, M., Lane, W. S., Sage, E. H., and Folkman, J. (1994a). Angiostatin: A circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harbor Symp. Quant. Biol. 59, 471-482.
40. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. (1994b). Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328.
41. Parangi, S., O'Reilly, M., Christofori, G., Holmgren, L., Grosfeld, J., Folkman, J., and Hanahan, D. (1996). Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl. Acad. Sci. USA 93, 2002-2007.
42. Pepper, M. S. (2001a). Extracellular proteolysis and angiogenesis. Thromb. Haemostasis 86, 346-355.
43. Pepper, M. S. (2001b). Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 21, 1104-1117.
44. Pepper, M. S., Montesano, R., Mandriota, S. J., Orci, L., and Vassalli, J. D. (1996). Angiogenesis: A paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein 49, 138-162.
45. Redlitz, A., Daum, G., and Sage, E. H. (1999). Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells. J. Vasc. Res. 36, 28-34.
46. Reeves, S. A., Chavez-Kappel, C., Davis, R., Rosenblum, M., and Israel, M. A. (1992). Developmental regulation of annexin II (Lipocortin 2) in human brain and expression in high grade glioma. Cancer Res. 52, 6871-6876.
47. Rozengurt, E. (1986). Early signals in the mitogenic response. Science 234, 161-166.
48. Sanders, T. C., and Seto, C. T. (1999). 4-Heterocyclohexanone-based inhibitors of the serine protease plasmin. J. Med. Chem. 42, 2969-2976.
49. Sawyer, S. T., and Cohen, S. (1985). Epidermal growth factor stimulates the phosphorylation of the calcium-dependent 35,000-dalton substrate in intact A-431 cells. J. Biol. Chem. 260, 8233-8236.
50. Sharma, M. C., and Shapiro, B. H. (1995). Purification and characterization of constituent testosterone 2 alpha- hydroxylase (cytochrome P450(2)alpha) from mouse liver. Arch. Biochem. Biophys. 316, 478-484.
51. Siever, D. A., and Erickson, H. P. (1997). Extracellular annexin II. Int. J. Biochem. Cell Biol. 29, 1219-1223.
52. Sim, B. K., O'Reilly, M. S., Liang, H., Fortier, A. H., He, W., Madsen, J. W., Lapcevich, R., and Nacy, C. A. (1997). A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res. 57, 1329-1334.
53. Sottrup-Jensen, L. H., Zajdel, M., Petersen, T. F., and Magnusson, S. (1978). The Primary Structure of Human Plasminogen: Isolation of Two Lysine-Binding Fragments and One Mini Plasminogen (MW 38,000) by Elastase-Catalyzed Specific Limited Proteolysis. Raven Press, New York.
54. Stack, M. S., Gately, S., Bafetti, L. M., Enghild, J. J., and Soff, G. A. (1999). Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem. J. 340, 77-84.
55. Tarui, T., Miles, L. A., and Takada, Y. (2001). Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. J. Biol. Chem. 276, 39562-39568.
56. Tressler, R. J., Updyke, T. V., Yeatman, T., and Nicolson, G. L. (1993). Extracellular annexin II is associated with divalent cation-dependent tumor cell-endothelial cell adhesion of metastatic RAW117 large-cell lymphoma cells. J. Cell. Biochem. 53, 265-276.
57. Troyanovsky, B., Levchenko, T., Mansson, G., Matvijenko, O., and Holmgren, L. (2001). Angiomotin: An angiostatin binding protein that regulates endothelial cell migration and tube formation. J. Cell Biol. 152, 1247-1254.
58. Vellucci, V. F., Germino, F. J., and Reiss, M. (1995). Cloning of putative growth regulatory genes from primary human keratinocytes by subtractive hybridization. Gene 166, 213-220.